Cargando…
Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
A retrospective analysis of 70 patients with triple-negative or hormone-resistant advanced breast carcinoma who had not previously received chemotherapy was carried out. Patients received oral vinorelbine 60 mg/m(2) on day 1 and 8, plus capecitabine 1000 mg/m(2) bid for 14 consecutive days every 3 w...
Autores principales: | Valerio, Maria Rosaria, Spadaro, Pietro, Arcanà, Concetta, Borsellino, Nicolò, Cipolla, Calogero, Vigneri, Paolo, Piazza, Dario, Gebbia, Vittorio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610004/ https://www.ncbi.nlm.nih.gov/pubmed/34840807 http://dx.doi.org/10.2144/fsoa-2020-0095 |
Ejemplares similares
-
Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis
por: Gebbia, Vittorio, et al.
Publicado: (2020) -
Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients’ Queries, Needs, Fears, and Actions Taken
por: Gebbia, Vittorio, et al.
Publicado: (2020) -
Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane
por: Ahn, Jin-Hee, et al.
Publicado: (2004) -
Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report
por: Gebbia, Vittorio, et al.
Publicado: (2021) -
All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
por: Tubiana-Mathieu, N, et al.
Publicado: (2009)